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Endoplasmic reticulum aminopeptidase 1 and 2 (ERAP1 and ERAP2) are key compo-
nents on the pathway that generates antigenic epitopes for presentation to cytotoxic
T-lymphocytes (CTLs). Coding single nucleotide polymorphisms (SNPs) in these enzymes
have been associated with pre-disposition to several major human diseases including
inflammatory diseases with autoimmune etiology, viral infections, and virally induced can-
cer.The function of these enzymes has been demonstrated to affect CTL and natural killer
cell responses toward healthy and malignant cells as well as the production of inflammatory
cytokines. Recent studies have demonstrated that SNPs in ERAP1 and ERAP2 can affect
their ability to generate or destroy antigenic epitopes and define the immunopeptidome. In
this review, we examine the potential role of these enzymes and their polymorphic states
on the generation of cytotoxic responses toward malignantly transformed cells. Given the
current state-of-the-art, it is possible that polymorphic variation in these enzymes may con-
tribute to the individual’s pre-disposition to cancer through altered generation or destruction
of tumor antigens that can facilitate tumor immune evasion.
Keywords: aminopeptidase, antigen presentation, cancer, SNP, cytotoxic responses, adaptive immunity, innate
immunity, polymorphism
PART I: ERAP1/2 AND CANCER
MECHANISMS USED BY THE IMMUNE SYSTEM TO FIGHT CANCER
The immune system plays a dual role in cancer, on one hand sup-
pressing tumor growth by eliminating cancer cells or inhibiting
their outgrowth, and on the other hand promoting tumor progres-
sion by selecting tumor cells able to survive inside an immuno-
competent host (1–7). The dynamic process that integrates these
opposing functions of the immune system – host protection and
tumor progression – is termed “cancer immunoediting” and con-
sists of three phases: (i) elimination, (ii) equilibrium, and (iii)
escape.
In the elimination phase, cells of innate and adaptive immu-
nity work together to identify and destroy nascent cancer cells,
before they become clinically apparent tumors. If a cancerous cell
variant is not eliminated in this phase, it may enter the equilib-
rium phase and remain in a state of functional dormancy under
control of cells and mediators of the adaptive immunity. In this
phase, the immune system controls tumor growth but does not
eliminate it. Cancer cells that acquire mutations can become: (i)
invisible to adaptive immunity, i.e., antigen-loss variants or tumor
cells that develop defects in antigen-processing or presentation,
(ii) insensitive to immune effector mechanisms, or (iii) induce an
immunosuppressive state within the tumor microenvironment,
enter the escape phase and grow progressively eventually becom-
ing visible tumors. The achievement of the last phase is indicative
of a failure in the adaptive immune cells to provide protection
from tumor development due to selection of poorly immunogenic
tumor cell variants during the equilibrium phase.
Many different cells belonging to the innate and adaptive
immunity play an active role in cancer control, from the earli-
est stages of transformation to the terminal phase of widespread
metastasis. The immune cells most involved in the host protec-
tion from development of cancer are natural killer (NK) cells and
cytotoxic T-lymphocytes (CTLs).
NK cells provide the first immune defense against infections
and tumor transformation through recognition and killing of
aberrant cells. Their function is finely tuned by the interaction
of activating and inhibitory receptors with their specific ligands
expressed on target cells (8). Activating receptors recognize lig-
ands expressed on stressed, infected, or transformed cells, whereas
inhibitory receptors, prevent NK cell activation upon interaction
with major histocompatibility complex (MHC) class I molecules
expressed on target cells (9–14). The reduced surface expression
of MHC class I molecules and acquisition of activating ligands in
virally infected and transformed cells make these cells particularly
vulnerable to NK cell-mediated killing.
CTLs constantly monitor peptide-MHC (pMHC) class I com-
plexes on the cell surface and eliminate virally infected or trans-
formed cells expressing novel peptides derived from abnormal
gene products. The generation of these peptides is central in the
regulation of CTL and NK cell responses against altered cells.
Aberrant antigenic peptide generation can lead to either immune
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evasion or to immune responses against normal cells, initiat-
ing or sustaining autoimmune reactions. Antigenic peptides are
generated by the concerted action of multiple components of a
biochemical pathway termed MHC class I antigen-processing and
presentation.
PATHWAY OF ANTIGEN-PROCESSING AND PRESENTATION
Antigen generation generally starts with the ubiquitin–proteasome
pathway where proteins are tagged for proteolytic destruction by
the proteasome although other cytosolic peptidases often play
important roles (15). The immune cell variant of the proteasome,
called immunoproteasome, is more efficient in generating longer
peptides, which are often N-terminally extended, compared to the
final antigenic epitopes (16). A fraction of these precursors are
transported by a specialized transporter [Transporter Associated
with antigen-Processing (TAP)] into the endoplasmic reticulum
(ER) for further processing. Inside the ER, the precursors are
further trimmed by ER-resident aminopeptidases, ER aminopepti-
dase 1 (ERAP1) and ER aminopeptidase 2 (ERAP2), which excise
the N-terminal extensions generating mature antigenic peptides
(17, 18). These peptides then bind onto nascent MHC class I mol-
ecules with the help of a multi-protein complex termed the peptide
loading complex. The pMHC class I complexes are then translo-
cated to the cell surface where they can interact with specialized
immune system (19).
ROLE OF ERAP1 AND ERAP2 IN THE GENERATION OF ANTIGENIC
EPITOPES
The key role of ERAP1 and ERAP2 in the generation of antigenic
epitopes has been repeatedly demonstrated in several cell lines and
mouse models. Reduction of ERAP1 expression by RNA interfer-
ence results in drastically defective presentation for some antigenic
epitopes (17, 18, 20, 21) and enhanced presentation or no effect
for others. Based on these studies, it has become apparent that
ERAP1 has a complex, multifaceted role on the generation of the
immunopeptidome (22–24).
In mice models, the complete loss of ERAAP expression (the
mouse homolog of ERAP1) specifically inhibited surface expres-
sion of MHC class I, but did not affect the expression of MHC
class II molecules (17). The expression of pMHC class I on the cell
surface depends on the quantity as well as the quality of the pep-
tide supply. In ERAAP-deficient cells, the reduction of MHC class
I molecules was due to faster dissociation of pMHC class I from
the cell surface rather than to a slower rate of pMHC class I assem-
ble in ER. As a result, ERAAP is important for generating optimal
peptides that yield stable pMHC class I complexes (25). More-
over, Hammer et al. observed that the absence of ERAAP disrupts
the pMHC class I repertoire in professional and non-professional
antigen-presenting cells. From in vivo studies emerged that ERAP1
plays an important role in immune response to viruses, either
enhancing or reducing CTL responses to particular viral epitopes
and, thereby, helping establish immunodominance hierarchies
(25). Undauntedly, expression of endogenous pMHC class I is
essential for the generation and maintenance of the normal CD8+
T cell responses. Splenocytes from ERAAP-deficient mice display
an alternative repertoire of peptides as well as differences in the sta-
bility of pMHC class I molecules characterized from a diminished
ability to elicit HY-specific CD8+ T cell responses. Interestingly,
immunization of ERAAP-deficient mice with splenocytes from
wild-type mice resulted in potent CD8+ T cell responses, suggest-
ing that ERAP1 plays an important role in modifying antigenic
peptides and, paradoxically, its absence enhances immunogenicity
(25, 26).
ERAP2, the second aminopeptidase demonstrated to be
involved in antigen trimming in the ER, is highly homologous
to ERAP1 but has distinct specificity (27–29). ERAP1 and ERAP2
have been suggested to perform antigenic peptide trimming in a
coordinated manner by forming a functional heterodimer (18, 30).
Saveanu et al. performed RNA interference to examine the roles
of ERAP1 and ERAP2 in trimming of various precursors of the
model HIV env epitope, using two different cell lines. The effect
of ERAP2 knockdown on cell-surface MHC class I expression and
epitope presentation was similar to that of ERAP1 knockdown,
suggesting equivalent functions of the two enzymes in the cells
studied. Also the greater effect of the double knockdown in some
cases suggests that each enzyme can function independently, so
that their effects are additive (18).
Overall, the exact effect of the ERAP1 and ERAP2 activities on
antigen presentation can be highly variable and difficult to predict.
Any factor that can influence the generation of the immunopep-
tidome may contribute to this, including the cell line used, the
MHC class I alleles, whether the cell contains immunoproteasomes
or constitutive proteasomes, the activities of cytosolic aminopep-
tidases and the sequence of the epitope studied. Regardless, ERAP1
and ERAP2 are undoubtedly important factors that influence
the generation of the immunopeptidome, with ERAP1 having a
dominant role (18, 22, 25).
ERAP1 IN INNATE IMMUNITY
ERAP1 has been found to play important roles in innate immune
responses. Namely, ERAP1 has been involved in the shedding of
cytokine receptors including the type I TNF receptor (TNFR1),
type I IL-6 receptor (IL-6Ra), and type II IL-II decoy recep-
tor (31–33). Additionally, macrophages were found to produce
a secreted form of ERAP1 in response to interferon-γ and
liposaccharides through a TLR-mediated mechanism that leads to
enhanced phagocytosis (34, 35). Similarly, human PBMCs exposed
to ERAP1 externally are activated and show enhanced production
of cytokines and chemokines, through mechanisms involving the
NLRP3 inflammasome (Aldhamen et al. J Innate Immunity, in
press). This secreted form of ERAP1 was found to be enzymatically
identical to the ER-retained form and only differ in glycosyla-
tion patterns consistent with maturation through the secretory
pathway. Since ERAP1 does not contain an ER retention signal it
has been hypothesized that it is normally retained inside the ER
through interactions with specific ER-resident proteins and can be
secreted when these interactions are saturated or disrupted (34).
The function of ERAP1 in regulating antigen presentation can
also lead to altered NK cell immune responses. ERAP1 knock-out
mice exhibit exaggerated innate immune responses early during
pathogen recognition and show increased activation of NK and
NKT cells and production of inflammatory cytokines (36). ERAP1
silencing in T cell lymphoma RMA results in tumor rejection in
syngeneic mice by triggering NK cells and subsequently T cell
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(CD4+ and CD8+) anti-tumor responses. This rejection does not
depend on a simple quantitative reduction in surface MHC class
I expression, but is rather the result of changes in the MHC class
I-peptide repertoire, because replacement of endogenous peptides
with high-affinity mature antigenic peptides was sufficient to res-
cue the inhibitory activity of NK cells (37). Furthermore, ERAP1
knock-out mice show high frequencies of terminally matured as
well as licensed NK cells expressing Ly49C and Ly49I receptors con-
sistent with enhanced NK activation by pro-inflammatory stimuli
in those mice (36). Together, these findings suggest an important
role for ERAP1 in modulating innate immune responses during
the earliest stages of pathogen recognition, a role that may be of
particular importance to immune responses toward malignantly
transformed cells.
ALTERED LEVELS OF ERAP1 AND ERAP2 CAN FACILITATE TUMOR
IMMUNE EVASION
The enzymatic activity and expression levels of the mouse
homolog of ERAP1, ERAAP, have been demonstrated to be key
for the immune evasion of tumor cells in two distinct murine
models. In one study, the authors showed that ERAP1 down-
regulation was sufficient to stimulate the cytotoxic activity of NK
cells and to result in tumor growth arrest (37). In another study,
down-regulation of ERAP1 elicited specific CTL responses against
a cryptic tumor-associated antigen that was normally destroyed
by ERAP1, resulting in tumor growth arrest and enhanced sur-
vival (38). These two studies clearly demonstrated that ERAP1
expression can be critical for immune evasion of solid tumors.
Moreover, by using cell lines with two different levels of ERAAP
expression levels James et al. established that the induction of
anti-tumor immune responses can be titrated based on ERAAP
activity, laying the groundwork for the hypothesis described
here (38).
In humans, defective expression of components of the antigen-
processing machinery has been associated with the progression
and clinical outcome in several types of cancer. The availability of
specific ERAP1 and ERAP2 antibodies has allowed researchers to
investigate the expression and tissue distribution of these enzymes
in a large number of tumor cells of various origins.
In one study, expression of ERAP1 and ERAP2 was detected in
all tumor cell lines examined, including melanoma and various
type of carcinomas, although at highly variable levels and inde-
pendently of each other (39). The amount of ERAP1 appears to be
more closely coordinated with cell-surface HLA class I molecules,
suggesting a secondary involvement of ERAP2 in the generation
of ligands for HLA class I molecules at least on quantitative lev-
els. However, this study did not consider that ERAP2 is missing
in 25% of the population (40). Notably, upregulation of ERAP1
and ERAP2 in ERAP-low tumor cells was found to enhance HLA
class I surface expression, suggesting that abnormal HLA class I
levels in tumor cells may result from defective expression of these
enzymes (39).
In another study, a heterogeneous expression of ERAP1 and
ERAP2 was detected in a panel of 28 melanoma cell lines (41).
A concordant expression between mRNA and proteins for these
genes was detected in many cell lines, except four in which an
aberrant ERAP2 transcript resulted in total absence of ERAP2
protein expression.
Expression of ERAP1 and ERAP2 was subsequently investigated
in 39 different cell types derived from 24 normal non-lymphoid
tissues and their malignant counterparts (42). In normal tissues,
expression of ERAP1 and ERAP2 was limited to epithelial com-
ponents. The two enzymes were co-expressed, singly expressed
or not expressed, depending on the cell type. HLA class I expres-
sion appeared to be independent of ERAP1 and ERAP2 expression
and only in nine cell types it was coordinated with both enzymes.
In tumor samples, the expression of either or both enzymes was
retained, lost, or acquired as compared to the normal counterparts,
depending on the tumor histotype. Loss of at least one enzyme
was the most frequent phenotype accounting for 86% tumors.
Remarkably, in four types of carcinomas (breast, ovary, liver, and
lung carcinomas) arising from normal counterparts co-expressing
ERAP1 and ERAP2, none of the 26 tested samples retained this
phenotype. ERAP1 was lost in all tested breast, ovary, and lung
carcinomas and in 6 out of 7 liver carcinoma samples tested,
whereas ERAP2 was retained only in 9 out of 26 samples. The
double-negative phenotype was significantly associated with lack
of detectable HLA class I molecules. Thus, in vivo transforma-
tion affects the expression of ERAP1 and ERAP2, together and
individually, leading to losses, gains, or imbalances.
In another study, expression of ERAP1 and ERAP2 was inves-
tigated in 300 normal kidney tissues and 334 renal cell carcinoma
lesions (43). A heterogeneous and discordant expression of the
two enzymes was detected in the different regions of the normal
kidney epithelium. In renal cell carcinomas, ERAP1 and ERAP2
appear to have a different behavior, being the first more frequently
up-regulated and the latter more frequently down-regulated, as
compared to the normal counterpart. None of the clinical para-
meters investigated was found to be associated with ERAP1 and
ERAP2 expression.
ERAP1 expression was also tested in 101 cervical carcinoma
patients including adenocarcinomas and squamous cell carcino-
mas, and correlated with clinical outcome (44). ERAP1 expression
was observed in most cases (85 out of 101) and overall never totally
lost. Partial ERAP1 loss was significantly associated with reduced
overall survival and disease free survival. In multivariate analysis,
ERAP1 down-regulation was demonstrated to be an independent
predictor for worse overall survival and disease free survival, and
significantly associated with lymph node metastases.
In another study, ERAP1 expression was examined in 50
esophageal carcinoma lesions and compared with clinico-
pathological parameters (45). In these tissues, ERAP1 expression
was lost or down-regulated in 20 and 28% of cases, respectively,
and significantly associated with the depth of tumor invasion. The
authors showed that ERAP1 expression was partially or totally lost
in cervical intraepithelial neoplasia and cervical squamous cell car-
cinoma as compared to normal epithelium of uterine cervix (46),
but association with clinical outcome was not investigated.
Taken together, these studies suggest that normal function
of ERAP1 and ERAP2 is required for NK cell- and T cell-
mediated anti-tumor immunity. As a result, the deregulated
expression of these enzymes found in tumors may cause improper
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antigen-processing and contribute to escape for host immune
surveillance.
PART II: ERAP1/2 SNPs
ERAP1/2 SNPs AND ASSOCIATION TO HUMAN DISEASE
Both ERAP1 and ERAP2 are naturally polymorphic and more
than a dozen coding single nucleotide polymorphisms (SNPs) in
their genes have been associated with pre-disposition to a variety
of human diseases primarily of autoimmune etiology (Figure 1;
Table 1). Such links are more evident for diseases that are strongly
associated with particular HLA class I alleles, implying that the
role of ERAP1 and ERAP2 in disease pathogenesis is through
the pathway of antigen-processing and presentation. The most
prominent example is the association of ERAP1 with Ankylosing
Spondylitis (AS), a chronic inflammatory rheumatopathy of the
lower spine with an autoimmune etiology. GWAS studies have
consistently shown that various ERAP1 coding SNPs are associ-
ated with pre-disposition to AS (47–49). The variants that appear
to confer risk susceptibility are: rs17482078-C (R725Q), rs30187-T
(K528R), rs2287987-T (M349V), rs26653-C (R127P), rs10050860-
C (D575N), and rs27044-G (Q730E), with each individual one
contributing odd ratios of about 1.3–1.4 (47, 48, 50). Due to the
strong linkage disequilibrium in the ERAP1/2 locus, specific hap-
lotypes have been associated with either pre-disposition or protec-
tion against AS. A pre-disposing haplotype has been proposed to
comprise of 730E, 575D, and 528K and a protective one of 528R,
276I, and 127P (51). Another pre-disposing haplotype also carries
an ERAP2 SNP (ERAP1 730Q, ERAP1 528K, and ERAP2 392N)
(52). Evans et al. showed that ERAP1 contribution to AS could be
primarily attributed to rs30187-T (528K), with secondary effects
found for rs10050860-C (575D) and rs17482078-C (725R) (48).
FIGURE 1 | Schematic representation of the crystal structure of ERAP1
(PDB code: 3MDJ). The amino acids at the sites of polymorphic variation
that have been found to either affect enzyme function or to associate with
pre-disposition to cancer are indicated by green spheres. The catalytic Zn(II)
atom at active site of the enzyme is shown by a red sphere. Note that the
polymorphic sites are distal to the active site and distributed throughout the
enzyme.
Most notably ERAP1 is associated with AS only in the presence
of at least one HLA-B27 allele, which is also the greatest known
AS risk factor (48, 49) suggesting that the pathogenic effect is
mediated through aberrant generation of HLA-B27 ligands either
in the context of arthritogenic self-peptides or the generation of
pro-inflammatory non-canonical HLA-B27 structures.
The association of ERAP1 with diseases in the context of spe-
cific HLA class I alleles is also observed in the cases of Behçet
disease (BD) and Psoriasis. A GWAS study in a Turkish popula-
tion, where BD is frequently encountered, identified rs10050860-T
(575N) and rs17482078-T (725Q) as increased risk variants, with
odd ratios significantly higher for HLA-B51 positive individuals
(53). Similarly to HLA-B27 and its association to AS, HLA-B51 is
the greatest known risk factor for BD. A recent study showed that
six positions within the peptide-binding cavity of MHC-I mol-
ecules are primarily responsible for the association of particular
HLA alleles (including HLA-B51) with BD, implying that aber-
rant peptide binding by HLA-B51 is central to the pathogenesis
of BD (54). Another GWAS study using a population of Euro-
pean ancestry demonstrated that rs30187-T (528K) increases risk
for psoriasis, but only in the presence of at least one copy of the
allele HLA-Cw*0602 (55). In addition to these well-established
cases, ERAP1 SNPs, with rs30187 as a prominent example, have
also been associated with other diseases. Specifically, the poly-
morphism rs30187-C (528R) has been associated with essential
hypertension (56) and the rs30187-T (528K) variant with Multiple
Sclerosis (57).
ERAP2 has been associated with AS independently of ERAP1.
Two functional SNPs have been described: coding rs2549782
(K392N) and rs2248374, a SNP that greatly influences ERAP2
expression (49). Furthermore, another ERAP2 SNP (rs2910686)
was associated with AS in HLA-B27-negative cases (49). ERAP1
and ERAP2 SNPs can form haplotypes that may be more relevant
to disease pathogenesis (52). The ERAP2 coding SNP rs2549782
(K392N) is also linked with preeclampsia and with resistance
to HIV-1 infection (58–61). The minor allele G is significantly
associated with preeclampsia in African-American and Australian
populations, but not in a Chilean population (58, 60, 61). A case-
control study in a cohort of Italian HIV-exposed seronegative
individuals showed that the homozygote GG genotype (encod-
ing Lys/Lys) is overrepresented in the HIV-exposed seronegative
sample (59). Recently, Kuiper et al. identified variants near the
ERAP2 locus that are associated with birdshot chorioretinopa-
thy (BCR) (62). This GWAS study identified rs7705093-T (OR:
2.3), to be in perfect linkage disequilibrium with rs10044354, a
variant that affects ERAP2 protein expression levels, with individ-
uals homozygous for the C allele showing almost none ERAP2
expression. BCR is a useful prototype of disease-HLA association
since it exhibits the strongest documented HLA class I association
for a human disease (>95% of cases carry the HLA-A29 allele)
implicating antigenic peptide processing and presentation in the
pathogenesis of this disease.
Overall, a very strong genetic link between ERAP1/2 SNPs
and HLA-associated autoimmunity has been established and has
contributed to our understanding of the pathogenesis of these
diseases. The genetic variability of ERAP1 and ERAP2 appears
to constitute part of the natural variability of immune responses
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Table 1 | Most common ERAP1 and ERAP2 SNPs, relation to disease, HLA, and functional consequences.
ERAP1/2 SNP Disease association HLA class I link Affects
ERAP1 rs3734016 (E56K) HPV-induced cervical carcinoma Expression levels
rs26653 (R127P) Ankylosing spondylitis, HPV-induced cervical carcinoma Expression levels
rs2287987 (M349V) Ankylosing spondylitis
rs30187 (K528R) Ankylosing spondylitis, psoriasis, essential hypertension,
multiple sclerosis
B*27 Cw*0602 Activity and specificity
rs10050860 (D575N) Ankylosing spondylitis, Behçet disease Activity
rs17482078 (R725Q) Ankylosing Spondylitis, Behçet disease B*51 Activity
rs27044 (Q730E) Ankylosing spondylitis, HPV-induced cervical carcinoma Activity and specificity
ERAP2 rs2549782 (K392N) Ankylosing spondylitis, preeclampsia, resistance to HIV
infection
Activity and specificity
rs2248374 (non-coding) Ankylosing spondylitis Expression levels
and may therefore contribute to pre-disposition to any number of
diseases actively fought by the adaptive immune response.
POLYMORPHIC STATE OF ERAP1/2 AFFECTS ENZYME FUNCTION AND
ANTIGEN GENERATION
The multitude of genetic and population studies linking ERAP1
and ERAP2 SNPs to pre-disposition to autoimmunity and viral
infections prompted several research groups to examine the effects
of the identified polymorphic variations on the enzyme’s biologi-
cal function and molecular mechanism. To date, most studies have
focused on the most well disease-associated SNPs, namely K528R,
D575N, R725Q, and Q730E.
The SNP at position 528 has been repeatedly demonstrated
to influence ERAP1 enzymatic activity. Various in vitro studies
have shown that the 528R variant exhibits less enzymatic activ-
ity, compared to the 528K (48, 63–66). Cell-based experiments
have also demonstrated the importance of that position: HeLa
cells transfected with ERAP1 528R and a HLA-B27 peptide pre-
cursor displayed a reduced amount of HLA-B27 molecules on
the cell surface compared to ERAP1 528K transfectants (64). Fur-
thermore, the presentation of specific MHC class I epitopes was
negatively influenced in cells transfected with the 528R variant and
their N-extended precursors, as shown by CTL activation assays
(67, 68).
Studies regarding polymorphic positions Q730E, D575N, and
R725Q have been more complicated to interpret. In vitro assays
have suggested that position 730 may or may not have an influ-
ence in the enzymatic activity, depending on the substrate used
(63, 64). Regardless, a cell-surface HLA class I expression assay
showed that this SNP could influence the generation of a spe-
cific HLA-B27-restricted epitope (64). Some studies showed that
position 575 does not influence ERAP1 activity in vitro (48, 63),
while another study showed that the 575N variant exhibits greater
activity compared to 575D (66). Regarding position 725, Evans
et al., using recombinant enzymes, showed that 725Q negatively
influences enzymatic activity toward a model fluorigenic peptide
substrate (48), but an in vitro CTL activation assay did not find
any influence of that position to the presentation of an HLA-B27
epitope (68). The complex landscape of functional effects found
for these SNPs may be attributed to differences in substrates or
assays used, or to differences in background SNPs that are not
always consistent between studies. Indeed, in several studies the
effects of ERAP1 SNPs have been found to be strongly epitope
dependent and to include effects on other mechanistic aspects of
ERAP1 peptide trimming, such as substrate inhibition and product
activation phenomena (64, 66, 69).
SNPs in ERAP1 and ERAP2 are often co-inherited as com-
plex haplotypes and may have strong synergism with each other.
Unfortunately, most functional studies until now have focused on
analyzing the effects of single SNPs and as a result the functional
effects of particular disease-associated ERAP1/ERAP2 haplotypes
are not always clear especially since the synergisms between indi-
vidual SNPs are not known. Recently, Seregin et al. analyzed two
ERAP1 haplotypes of five SNPs for their effects on HLA-B27
restricted presentation in relation to the pathogenesis of AS and
concluded that the high-risk haplotype resulted in reduction in
presentation of multiple antigens (70). In another study, Reeves
et al. identified nine separate naturally occurring haplotypes in a
small population sample based on the five most disease-related
SNPs (positions: M349V, K528R, D575N, R725Q, and Q730E)
(67). They evaluated the trimming activity of these alleles using
a CTL activation assay and showed that each allele exhibits a
different activity that is not only dependent on the allele itself
but also on the N-terminal extension of the peptide. This study
was recently extended to AS patients, showing that ERAP1 hap-
lotypes were clearly stratified in individuals with AS compared
to healthy controls and that these functional alleles were poor
in generating optimal peptide ligands for HLA-B*2705 (71). A
study focusing on the combined effects of positions 528 and
575 showed that the latter position was dominant in determin-
ing enzyme activity (66). Recently, Chen et al. demonstrated that
the polymorphic variation in position 730 is critical for rescu-
ing the reduced CTL activation found in the presence of the
528R SNP (68). Overall, ample evidence for strong synergism
amongst ERAP1 SNPs are available, although we have very lit-
tle insight on how these SNPs that are scattered all throughout
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the ERAP1 structure can cooperate to affect the activity of the
enzyme.
The influence of ERAP1 polymorphic context has also been
studied in the context of the HLA-B27 restricted immunopep-
tidome and the pathogenesis of AS. Garcia-Medel et al. showed
that the presence of ERAP1 with all the AS-pre-disposing poly-
morphisms (349M, 528K, 575D, 725R, and 730Q) ensured efficient
peptide trimming and a higher HLA-B27 stability, compared to
the ERAP1 with the AS-protective SNPs (349V, 528R, 575N, 725Q,
and 730E) (72). Extending this work, Martin-Esteban et al. showed
that synergism between SNPs at positions 528 and 575 can have
important effects on cell-surface HLA-B27 presented ligands and
more recently Garcia-Medel et al. showed that the particular B27
subtype is critical in determining these effects (66, 73). It appears
that the interplay between ERAP1 SNPs and HLA class I subtypes
is the key to determining the cell-surface immunopeptidome and
concomitant cytotoxic responses.
Two ERAP2 SNPs have been shown to have specific effects
on the enzyme’s biological function: the coding polymorphism
rs2549782 (N392K) and the non-coding rs2248374. ERAP2 poly-
morphism N392K alters the activity and specificity of ERAP2 in a
manner much more pronounced compared to the effects described
for all coding SNPs of ERAP1 (74). Specifically, in vitro cell-based
analysis showed that the 392N variant is much more effective in
trimming hydrophobic N-terminal residues from antigenic pep-
tide precursors compared to 392K. In contrast, the rs2248374-G
allele can determine ERAP2 expression levels by inducing mRNA
instability and non-sense mediated decay (40). The biological
consequence of that frequently encountered allele (about 0.5 fre-
quency in six different populations studied) has also been demon-
strated; rs2248374-G homozygotes produce no detectable ERAP2
and have reduced levels of MHC class I expression on B-cell
surfaces.
Similarly to ERAP1, these ERAP2 SNPs often organize to dis-
tinct haplotypes. SNP rs2248374 is in linkage disequilibrium with
rs2549782 in various populations studied, thus effectively allowing
only the expression of 392K variant (40). A noteworthy exception
is the Chilean population where the two SNPs are not in link-
age disequilibrium, allowing the expression of 392N variant (61).
Nevertheless, no Chilean genotype was found homozygous for the
392N allele, implying a possible negative selection for individuals
that are homozygous for that allele. Interestingly, the recent asso-
ciation of ERAP2 expression with pre-disposition to the inflam-
matory autoimmune disease BCR solidified the idea that ERAP2
polymorphic variation and its effects on antigen-processing may
have important repercussions on adaptive immune responses (62).
ERAP1 SNPs AND PRE-DISPOSITION TO VIRALLY INDUCED CANCER
Genetic variations in genes encoding components of the antigen-
processing pathway have been associated with risk of occurrence
malignancy and in particular with cervical carcinoma. Mehta
and colleagues analyzed the effect of different ERAP1 SNPs
and haplotype combinations on the risk of developing human
papillomavirus (HPV)-induced cervical carcinoma.
In the first study, the authors identified two common ERAP1
polymorphisms, R127P and Q730E, significantly associated with
increased risk of cervical cancer (75). A haplotype combination
consisting of four SNPs, including the minor alleles at R127P and
Q730E loci and a major allele at the TAP1 R651C and LMP7 Q145K
loci, was significantly associated with a threefold increased cervi-
cal carcinoma risk (75). The authors estimated that 12% of all
cervical carcinoma cases were attributable to the occurrence of
this haplotype combination (75).
In a subsequent study, the same group investigated which
genetic ERAP1 variation affected tumor progression and overall
survival in cervical carcinoma patients, and provided the first indi-
cation of association of ERAP1 SNPs with ERAP1 protein expres-
sion (76). Genotype distributions at the R127P, I276M and K528R
were significantly associated with the presence of lymph node
metastases. Heterozygosity of E56K and minor allele homozygos-
ity at the R127P loci were significantly associated with decreased
overall survival. Multivariate analysis performed on E56K and
R127P genotypes combined with prognostic factors, revealed that
the two SNPs loci were not independent predictors of survival. The
R127P variant and the E56K–R127P haplotype were significantly
associated with ERAP1 protein expression, with heterozygosity of
both individual SNPs and the haplotype consisting of a major allele
at the E56K locus and a minor allele at the R127P, being signifi-
cantly associated with normal ERAP1 expression and better overall
survival. Heterozygosity for E56K–R127P haplotype was found to
be an independent predictor for overall survival and lymph node
metastasis.
The association between ERAP1 SNPs and cervical carcinoma
risk or patient survival may be explained by different mechanisms,
all related to altered ERAP1 function. Genetic variations at these
individual SNPs have been found to affect the expression and
stability of transcripts and proteins, to reduce trimming activ-
ity or modify substrate specificity (48, 64, 76). All these effects
may affect the ability of HPV to establish persistent infections,
but also the ability of transformed cells to evade immune sur-
veillance. The information gathered by these studies has helped
to establish a new paradigm on how the polymorphic variation
of the adaptive immune system can play a role on both cancer
development and prognosis. Although the importance of viral
control in the pre-disposition to virally induced cancer is easy
to understand, this work has opened the possibility that variable
immune responses in the population may also play important roles
to cancer pre-disposition.
ERAP1 AND ERAP2 SNPs AND PRE-DISPOSITION TO CANCER – A
HYPOTHESIS
Current knowledge on the roles of ERAP1 and ERAP2 in the
human immune response have gradually led to the maturation
of the hypothesis that the naturally occurring polymorphic vari-
ation in ERAP1 and ERAP2 may play significant roles in the
pre-disposition to certain cancers, as well as their progression and
prognosis. More specifically, the rational behind this hypothesis is
based on the following points:
1. CTL and NK cell responses against malignantly transformed
cells are important for eradicating tumor cells often at the early
stages of carcinogenesis.
2. Establishment of solid tumors often requires adaptive mea-
sures from the transformed cells that lead to the evasion of
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immune responses. Such adaptive measures include changes in
antigen-processing and presentation in order to suppress the
presentation of tumor-specific antigenic epitopes while also
evading NK-cell recognition.
3. Polymorphic variation in ERAP1 and ERAP2, alters their func-
tion and their ability to generate antigenic peptides and controls
cytotoxic reactions against antigen-presenting cells. This is now
well established in autoimmunity and viral infections.
4. ERAP1 and ERAP2 expression levels, which undoubtedly affect
effective enzyme activity, are consistently altered in tumors,
presumably as an adaptive measure for immune evasion.
5. ERAP1 function can regulate innate immune responses and
the production of inflammatory cytokines, a function that
can either help eradicate cancer cells or contribute to localize
inflammation that can promote tumor growth.
As a result, the polymorphic variability in ERAP1 and ERAP2
may affect the severity of early cytotoxic responses toward trans-
formed cells and influence their chances to accrue genetic adapta-
tions that will allow them to evade the immune system (Figure 2).
Individuals carrying particular ERAP haplotypes in combination
with specific HLA class I alleles may therefore be more prone to
carcinogenesis, not because of facilitated malignant transforma-
tion but because they have an immune system that is less effec-
tive in mounting strong cytotoxic responses against cancer cells.
Additionally, the function of ERAP1 in regulating inflammatory
cytokine production may contribute to these effects by influencing
the inflammatory state of the tumor microenvironment.
CONTROLLING ERAP1 AND ERAP2 ACTIVITY FOR TREATING CANCER
In addition to the possible role of the activity of ERAP1 and ERAP2
on the normal immune control of cancer, a series of recent studies
have highlighted that these two enzymes may be important phar-
macological targets for boosting immune responses to established
cancers. In one study, the genetic down-regulation of ERAP1 in
cancer cells that establish solid tumors in mice resulted potent
NK cell-mediated cytotoxic responses (37). In another study, the
genetic down-regulation of ERAP1 in cancer cells resulted in
strong CTL responses against a cryptic tumor antigen normally
destroyed by over-active ERAP1 (38). In both studies, tumor
FIGURE 2 | Schematic representation of two extreme scenarios
leading to either effective cytotoxic responses against a cancer cell
(A) or immune evasion (B). A tumor-specific antigenic epitope or its
N-terminal extended precursor is generated by the proteasome and
transported into the ER. There, it is further processed by ERAP1/ERAP2
alleles. In case A, the “green” and “cyan” allele effectively generate the
mature epitope (red line), which is then loaded onto nascent empty MHC
class I and presented to the cell-surface, activating antigen-specific T cells.
In case B, hyper-active or hypo-active ERAP1/ERAP2 alleles (in red and
orange) either fail to produce the mature epitope or destroy it by generating
peptides too small to bind onto MHC class I molecules. As a result, the
epitope is not presented on the cell surface and no T cell activation occurs,
facilitating immune evasion. The allelic state of ERAP1 and ERAP2 can
therefore influence anti-tumor adaptive immune responses pre-disposing
individuals to certain cancers by facilitating immune evasion at early stages
of malignant development.
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growth was halted resulting in clear therapeutic outcome in mice.
In the latter study, the effect was partially reproduced using the
small molecular weight metallopeptidase inhibitor Leucinethiol
(38). A recently developed potent ERAP1/ERAP2 inhibitor was
successfully used to induce CTL responses against the cancer cells
used in that study (77). Apart from the obvious extension of
these studies conclusions to cancer immunotherapy, one addi-
tional conclusion may be drawn: inhibition of ERAP1 activity
was not necessarily complete in either study, indicating that even
moderate modulation of ERAP1 activity, such as seen in the nor-
mal polymorphic variation in this enzyme, may be sufficient to
radically affect the potential of cancer immune surveillance.
CONCLUDING REMARKS – FUTURE RESEARCH DIRECTIONS
In summary, we review the state-of-the-art on the role of ERAP1
and ERAP2 in adaptive and innate immune responses and their
role on disease pathogenesis. Combination of knowledge on the
role of polymorphic variation on those enzymes and disease
pre-disposition with their role in cancer development has led
to the formulation of a hypothesis on their direct role on can-
cer pre-disposition and prognosis. If this hypothesis holds to be
true, haplotype analysis of components of the antigen-processing
machinery may contribute to our understanding of cancer pre-
disposition and complement other genetic findings on biochem-
ical pathways that control malignant transformation. Because of
the genetic heterogeneity of tumors however, it may be difficult to
discern such effects at the tumor level and population studies may
have to focus on the overall influence of this genetic locus on pre-
disposition to specific cancers. Ongoing and future GWAS studies
on cancer patients may yet reveal the importance of immune sys-
tem variation to developing and fighting cancer, contributing to
personalized treatments.
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